Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications

Bortezomib (BTZ) is a first-in-class reversible and selective proteasome inhibitor. It inhibits the ubiquitin proteasome pathway that leads to the degradation of many intracellular proteins. Initially, BTZ was FDA approved for the treatment of refractory or relapsed multiple myeloma (MM) in 2003. La...

Descripción completa

Detalles Bibliográficos
Autores principales: Alwahsh, Mohammad, Farhat, Joviana, Talhouni, Shahd, Hamadneh, Lama, Hergenröder, Roland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Leibniz Research Centre for Working Environment and Human Factors 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043448/
https://www.ncbi.nlm.nih.gov/pubmed/36998701
http://dx.doi.org/10.17179/excli2022-5653

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043448/
https://www.ncbi.nlm.nih.gov/pubmed/36998701
http://dx.doi.org/10.17179/excli2022-5653

Ejemplares similares